{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:14:49Z","timestamp":1793060089032,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      This subgroup analysis of the PERSEUS study aimed to describe the effectiveness of cefiderocol treatment in the early access programme in Spain in patients infected by\n                      <jats:italic>Stenotrophomonas maltophilia<\/jats:italic>\n                      ,\n                      <jats:italic>Burkholderia cepacia<\/jats:italic>\n                      complex (Bcc) or\n                      <jats:italic>Achromobacter<\/jats:italic>\n                      species.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In the retrospective, observational, multicentre PERSEUS study in Spain, the effectiveness and safety of cefiderocol treatment administered for at least 72\u00a0h up to 28 days in patients infected by Gram-negative bacteria, except\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      spp., in the early access programme was investigated. Patient demographics and baseline clinical characteristics, cefiderocol use, clinical cure at end of treatment, all-cause mortality at Day 28 were the main outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 20 patients had\n                      <jats:italic>S. maltophilia<\/jats:italic>\n                      infections, and 14 patients had other rare glucose non-fermenters (Bcc 8,\n                      <jats:italic>Achromobacter<\/jats:italic>\n                      spp. 5,\n                      <jats:italic>Ralstonia mannitolilytica<\/jats:italic>\n                      1). The median (interquartile range [IQR]) age was 60.5 (48.0\u201365.5) years and 49.5 (33.0\u201359.0) years for patients with\n                      <jats:italic>S. maltophilia<\/jats:italic>\n                      and other rare non-fermenters, respectively. The majority of patients had respiratory tract infections (\n                      <jats:italic>S. maltophilia<\/jats:italic>\n                      55%; other rare non-fermenters 71.4%), and median (IQR) duration of cefiderocol treatment was 10.0 (6.5\u201313.5) days and 8.0 (6\u201314) days, respectively. Clinical cure rates were 70%, 62.5% and 80.0% for patients with\n                      <jats:italic>S. maltophilia<\/jats:italic>\n                      , Bcc and\n                      <jats:italic>Achromobacter<\/jats:italic>\n                      spp., respectively. Corresponding 28-day all-cause mortality rates were 30.0%, 37.5% and 40.0%, respectively. One patient with\n                      <jats:italic>R. mannitolilytica<\/jats:italic>\n                      had clinical cure and survived to Day 28.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cefiderocol is an important addition to the limited treatment options for patients infected by these rare glucose non-fermenting Gram-negative bacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT05789199 (Registration date: 16 February 2023).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10096-025-05109-5","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T13:41:28Z","timestamp":1742823688000},"page":"1367-1374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study"],"prefix":"10.1007","volume":"44","author":[{"given":"Julian","family":"Torre-Cisneros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen De La Fuente","family":"Martos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Javier","family":"Gonzalez Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Verardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Karas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"issue":"6","key":"5109_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/QCO.0000000000000977","volume":"36","author":"D Koulenti","year":"2023","unstructured":"Koulenti D, Vandana KE, Rello J (2023) Current viewpoint on the epidemiology of nonfermenting Gram-negative bacterial strains. Curr Opin Infect Dis 36(6):545\u2013554. https:\/\/doi.org\/10.1097\/QCO.0000000000000977","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"5109_CR2","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/QCO.0000000000000975","volume":"36","author":"MF Mojica","year":"2023","unstructured":"Mojica MF, Bonomo RA, van Duin D (2023) Treatment approaches for severe Stenotrophomonas maltophilia infections. Curr Opin Infect Dis 36(6):572\u2013584. https:\/\/doi.org\/10.1097\/QCO.0000000000000975","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"5109_CR3","doi-asserted-by":"publisher","first-page":"e0003019","DOI":"10.1128\/CMR.00030-19","volume":"34","author":"JS Brooke","year":"2021","unstructured":"Brooke JS (2021) Advances in the microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev 34(3):e0003019. https:\/\/doi.org\/10.1128\/CMR.00030-19","journal-title":"Clin Microbiol Rev"},{"key":"5109_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drup.2016.07.003","volume":"28","author":"KA Rhodes","year":"2016","unstructured":"Rhodes KA, Schweizer HP (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82\u201390. https:\/\/doi.org\/10.1016\/j.drup.2016.07.003","journal-title":"Drug Resist Updat"},{"issue":"1","key":"5109_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s13054-019-2649-5","volume":"23","author":"P Guerci","year":"2019","unstructured":"Guerci P, Bellut H, Mokhtari M, AZUREA research network et al (2019) Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care 23(1):371. https:\/\/doi.org\/10.1186\/s13054-019-2649-5","journal-title":"Crit Care"},{"issue":"4","key":"5109_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1164\/rccm.200712-1834OC","volume":"178","author":"S Murray","year":"2008","unstructured":"Murray S, Charbeneau J, Marshall BC, LiPuma JJ (2008) Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 178(4):363\u2013371. https:\/\/doi.org\/10.1164\/rccm.200712-1834OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"5109_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/antibiotics11050612","volume":"11","author":"L van den Bogaart","year":"2022","unstructured":"van den Bogaart L, Manuel O (2022) Antibiotic therapy for difficult-to-treat infections in lung transplant recipients: a practical approach. Antibiotics (Basel) 11(5):612. https:\/\/doi.org\/10.3390\/antibiotics11050612","journal-title":"Antibiotics (Basel)"},{"issue":"12","key":"5109_CR8","doi-asserted-by":"publisher","first-page":"e0041623","DOI":"10.1128\/iai.00416-23","volume":"91","author":"CE Billiot","year":"2023","unstructured":"Billiot CE, Novak L, McDaniel MS, Lindgren NR, Swords WE (2023) Pathogenesis of Achromobacter xylosoxidans respiratory infections: colonization, persistence, and transcriptome profiling in synthetic cystic fibrosis sputum medium. Infect Immun 91(12):e0041623. https:\/\/doi.org\/10.1128\/iai.00416-23","journal-title":"Infect Immun"},{"issue":"5","key":"5109_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/ppul.26359","volume":"58","author":"V Dacc\u00f2","year":"2023","unstructured":"Dacc\u00f2 V, Alicandro G, Consales A et al (2023) Cepacia syndrome in cystic fibrosis: a systematic review of the literature and possible new perspectives in treatment. Pediatr Pulmonol 58(5):1337\u20131343. https:\/\/doi.org\/10.1002\/ppul.26359","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"5109_CR10","doi-asserted-by":"publisher","first-page":"e0242221","DOI":"10.1128\/jcm.02422-21","volume":"60","author":"T Garrigos","year":"2022","unstructured":"Garrigos T, Dollat M, Magallon A et al (2022) Distribution of Achromobacter species in 12 French cystic fibrosis centers in 2020 by a retrospective MALDI-TOF MS spectrum analysis. J Clin Microbiol 60(6):e0242221. https:\/\/doi.org\/10.1128\/jcm.02422-21","journal-title":"J Clin Microbiol"},{"issue":"9","key":"5109_CR11","doi-asserted-by":"publisher","first-page":"e45909","DOI":"10.7759\/cureus.45909","volume":"15","author":"S \u00d6zer","year":"2023","unstructured":"\u00d6zer S, Akin M, Yasti AC (2023) A rare bacteremia in a burn patient: a case report of Achromobacter xylosoxidans and denitrificans. Cureus 15(9):e45909. https:\/\/doi.org\/10.7759\/cureus.45909","journal-title":"Cureus"},{"issue":"7","key":"5109_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/tropicalmed8070335","volume":"8","author":"BJ Shen","year":"2023","unstructured":"Shen BJ, Wang JT, Chang HT, Chang SC, Liao CH (2023) Single-center experience of control of ventilator-circuit-transmitted Burkholderia cepacia outbreak in an intensive care unit. Trop Med Infect Dis 8(7):335. https:\/\/doi.org\/10.3390\/tropicalmed8070335","journal-title":"Trop Med Infect Dis"},{"issue":"7","key":"5109_CR13","doi-asserted-by":"publisher","first-page":"e0037923","DOI":"10.1128\/aac.00379-23","volume":"67","author":"M Olbrecht","year":"2023","unstructured":"Olbrecht M, Echahidi F, Pi\u00e9rard D et al (2023) In vitro susceptibility of Achromobacter species isolated from cystic fibrosis patients: a 6-year survey. Antimicrob Agents Chemother 67(7):e0037923. https:\/\/doi.org\/10.1128\/aac.00379-23","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"5109_CR14","doi-asserted-by":"publisher","first-page":"e0034623","DOI":"10.1128\/aac.00346-23","volume":"67","author":"M Takemura","year":"2023","unstructured":"Takemura M, Nakamura R, Ota M et al (2023) In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. Antimicrob Agents Chemother 67(12):e0034623. https:\/\/doi.org\/10.1128\/aac.00346-23","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"5109_CR15","doi-asserted-by":"publisher","first-page":"e0198123","DOI":"10.1128\/spectrum.01981-23","volume":"11","author":"MA Pfaller","year":"2023","unstructured":"Pfaller MA, Shortridge D, Carvalhaes CG, Castanheira M (2023) Trends in the susceptibility of U.S. Acinetobacter baumannii-calcoaceticus species complex and Stenotrophomonas maltophilia isolates to minocycline, 2014\u20132021. Microbiol Spectr 11(6):e0198123. https:\/\/doi.org\/10.1128\/spectrum.01981-23","journal-title":"Microbiol Spectr"},{"issue":"1","key":"5109_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.37201\/req\/098.2023","volume":"37","author":"D Gij\u00f3n","year":"2024","unstructured":"Gij\u00f3n D, Garc\u00eda-Castillo J, Fern\u00e1ndez-L\u00f3pez MC et al (2024) In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal. Rev Esp Quimioter 37(1):69\u201377. https:\/\/doi.org\/10.37201\/req\/098.2023","journal-title":"Rev Esp Quimioter"},{"issue":"10","key":"5109_CR17","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/antibiotics10101226","volume":"10","author":"J Gibb","year":"2021","unstructured":"Gibb J, Wong DW (2021) Antimicrobial treatment strategies for Stenotrophomonas maltophilia: a focus on novel therapies. Antibiotics (Basel) 10(10):1226. https:\/\/doi.org\/10.3390\/antibiotics10101226","journal-title":"Antibiot (Basel)"},{"key":"5109_CR18","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403","DOI":"10.1093\/cid\/ciae403"},{"issue":"Suppl 1","key":"5109_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.37201\/req\/s01.11.2023","volume":"36","author":"R Cant\u00f3n","year":"2023","unstructured":"Cant\u00f3n R, Ruiz-Garbajosa P (2023) Treatment guidelines for multidrug-resistant Gram-negative microorganisms. Rev Esp Quimioter 36(Suppl 1):46\u201351. https:\/\/doi.org\/10.37201\/req\/s01.11.2023","journal-title":"Rev Esp Quimioter"},{"issue":"2","key":"5109_CR20","doi-asserted-by":"publisher","first-page":"e0271221","DOI":"10.1128\/spectrum.02712-21","volume":"10","author":"D Shortridge","year":"2022","unstructured":"Shortridge D, Streit JM, Mendes R, Castanheira M (2022) In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program. Microbiol Spectr 10(2):e0271221. https:\/\/doi.org\/10.1128\/spectrum.02712-21","journal-title":"Microbiol Spectr"},{"key":"5109_CR21","doi-asserted-by":"publisher","unstructured":"Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF (2022) In vitro susceptibility of Gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019. Antimicrob Agents Chemother 66(2):e0199021 https:\/\/doi.org\/10.1128\/aac.01990-21. Erratum in: (2023) Antimicrob Agents Chemother 67(6):e0042723 https:\/\/doi.org\/10.1128\/aac.00427-23","DOI":"10.1128\/aac.01990-21"},{"key":"5109_CR22","doi-asserted-by":"publisher","unstructured":"Jean-Pierre V, Sorlin P, Pantel A, Collaborative study group on antimicrobial resistance of Achromobacter spp. et al (2024) Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains. Ann Clin Microbiol Antimicrob 23(1):54 https:\/\/doi.org\/10.1186\/s12941-024-00709-z","DOI":"10.1186\/s12941-024-00709-z"},{"key":"5109_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jgar.2024.01.023","volume":"36","author":"MM Tunney","year":"2024","unstructured":"Tunney MM, Elborn JS, McLaughlin CS, Longshaw CM (2024) In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis. J Glob Antimicrob Resist 36:407\u2013410. https:\/\/doi.org\/10.1016\/j.jgar.2024.01.023","journal-title":"J Glob Antimicrob Resist"},{"key":"5109_CR24","doi-asserted-by":"publisher","unstructured":"Torre-Cisneros J, Almirante B, de la Fuente MartosC et al (2025) Real-world effectiveness and safety of Cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study. Eur J Clin Microbiol & Infect Dis. https:\/\/doi.org\/10.1007\/s10096-025-05108-6","DOI":"10.1007\/s10096-025-05108-6"},{"issue":"7","key":"5109_CR25","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","volume":"75","author":"M Delgado-Valverde","year":"2020","unstructured":"Delgado-Valverde M, Conejo MDC, Serrano L, Fern\u00e1ndez-Cuenca F, Pascual \u00c1 (2020) Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother 75(7):1840\u20131849. https:\/\/doi.org\/10.1093\/jac\/dkaa117","journal-title":"J Antimicrob Chemother"},{"key":"5109_CR26","doi-asserted-by":"publisher","unstructured":"Sarzynski SH, Warner S, Sun J et al (2022) Trimethoprim-sulfamethoxazole versus levofloxacin for Stenotrophomonas maltophilia infections: a retrospective comparative effectiveness study of electronic health records from 154 US hospitals. Open Forum Infect Dis 9(2):ofab644 https:\/\/doi.org\/10.1093\/ofid\/ofab644. Erratum in: (2023) Open Forum Infect Dis 10(4):ofad198 https:\/\/doi.org\/10.1093\/ofid\/ofad198","DOI":"10.1093\/ofid\/ofab644"},{"key":"5109_CR27","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.2147\/IDR.S416678","volume":"16","author":"P Boonmee","year":"2023","unstructured":"Boonmee P, Nasomsong W, Lorchirachoonkul N et al (2023) The activities of antimicrobials against Stenotrophomonas maltophilia isolates and evaluation of clinical outcomes among treatment regimens in patients with Stenotrophomonas maltophilia infections: A retrospective multicenter cohort study. Infect Drug Resist 16:5173\u20135184. https:\/\/doi.org\/10.2147\/IDR.S416678","journal-title":"Infect Drug Resist"},{"issue":"7","key":"5109_CR28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/10600280231201850","volume":"58","author":"EC Hevia","year":"2024","unstructured":"Hevia EC, Wooten L, Carr AL (2024) Trimethoprim\/sulfamethoxazole vs minocycline for the treatment of nonurinary monomicrobial Stenotrophomonas maltophilia infections in hospitalized patients. Ann Pharmacother 58(7):698\u2013704. https:\/\/doi.org\/10.1177\/10600280231201850","journal-title":"Ann Pharmacother"},{"issue":"2","key":"5109_CR29","doi-asserted-by":"publisher","first-page":"106367","DOI":"10.1016\/j.ijantimicag.2021.106367","volume":"58","author":"SJ Junco","year":"2021","unstructured":"Junco SJ, Bowman MC, Turner RB (2021) Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim\/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy. Int J Antimicrob Agents 58(2):106367. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106367","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"5109_CR30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1186\/s12879-019-4394-4","volume":"19","author":"EJ Kim","year":"2019","unstructured":"Kim EJ, Kim YC, Ahn JY et al (2019) Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis 19(1):754. https:\/\/doi.org\/10.1186\/s12879-019-4394-4","journal-title":"BMC Infect Dis"},{"key":"5109_CR31","doi-asserted-by":"publisher","first-page":"204993612311742","DOI":"10.1177\/20499361231174292","volume":"10","author":"MM Chambers","year":"2023","unstructured":"Chambers MM, Gutowski CJ, Doktor K (2023) Cefiderocol for Stenotrophomonas maltophilia prosthetic joint infection: a case report. Ther Adv Infect Dis 10:20499361231174292. https:\/\/doi.org\/10.1177\/20499361231174292","journal-title":"Ther Adv Infect Dis"},{"issue":"4","key":"5109_CR32","doi-asserted-by":"publisher","first-page":"ofad174","DOI":"10.1093\/ofid\/ofad174","volume":"10","author":"AJ Hsu","year":"2023","unstructured":"Hsu AJ, Simner PJ, Bergman Y, Mathers AJ, Tamma PD (2023) Successful treatment of persistent Stenotrophomonas maltophilia bacteremia with cefiderocol in an infant. Open Forum Infect Dis 10(4):ofad174. https:\/\/doi.org\/10.1093\/ofid\/ofad174","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"5109_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/medicina60010088","volume":"60","author":"T Lupia","year":"2024","unstructured":"Lupia T, Carnevale-Schianca F, Vita D et al (2024) Stenotrophomonas maltophilia infections in haematological malignancies and hematopoietic stem cell transplantation: a case series including cefiderocol-based regimens. Med (Kaunas) 60(1):88. https:\/\/doi.org\/10.3390\/medicina60010088","journal-title":"Med (Kaunas)"},{"key":"5109_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jgar.2023.05.013","volume":"34","author":"F Medioli","year":"2023","unstructured":"Medioli F, Casali E, Viscido A, Pistolesi V, Venditti M, Oliva A (2023) First case of persistent Stenotrophomonas maltophilia bacteraemia due to septic thrombosis successfully treated with a cefiderocol-containing regimen. J Glob Antimicrob Resist 34:5\u20138. https:\/\/doi.org\/10.1016\/j.jgar.2023.05.013","journal-title":"J Glob Antimicrob Resist"},{"issue":"5","key":"5109_CR35","doi-asserted-by":"publisher","first-page":"e38613","DOI":"10.7759\/cureus.38613","volume":"15","author":"MH Rashid","year":"2023","unstructured":"Rashid MH, Bukhari SNY, Mousa A, Aziz AA, Hakobyan K (2023) Cefiderocol as a treatment option for Stenotrophomonas maltophilia causing hospital-acquired\/ventilator-associated pneumonia. Cureus 15(5):e38613. https:\/\/doi.org\/10.7759\/cureus.38613","journal-title":"Cureus"},{"issue":"12","key":"5109_CR36","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s00277-022-05006-3","volume":"101","author":"E Zappulo","year":"2022","unstructured":"Zappulo E, Grimaldi F, Paolillo R, et al (2022) Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy. Ann Hematol 101(12):2805\u20132806. https:\/\/doi.org\/10.1007\/s00277-022-05006-3","journal-title":"Ann Hematol"},{"issue":"1","key":"5109_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40121-020-00385-4","volume":"10","author":"M Bodro","year":"2021","unstructured":"Bodro M, Hern\u00e1ndez-Meneses M, Ambrosioni J et al (2021) Salvage treatment with cefiderocol regimens in two intravascular foreign body infections by MDR Gram-negative pathogens, involving non-removable devices. Infect Dis Ther 10(1):575\u2013581. https:\/\/doi.org\/10.1007\/s40121-020-00385-4","journal-title":"Infect Dis Ther"},{"issue":"11","key":"5109_CR38","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/ppul.24945","volume":"55","author":"AB Gainey","year":"2020","unstructured":"Gainey AB, Burch AK, Brownstein MJ, et al (2020) Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol 55(11):2990\u20132994. https:\/\/doi.org\/10.1002\/ppul.24945","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"5109_CR39","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/antibiotics11121686","volume":"11","author":"G La Bella","year":"2022","unstructured":"La Bella G, Salvato F, Minafra GA et al (2022) Successful treatment of aortic endocarditis by Achromobacter xylosoxidans with cefiderocol combination therapy in a non-Hodgkin lymphoma patient: case report and literature review. Antibiotics(Basel) 11(12):1686. https:\/\/doi.org\/10.3390\/antibiotics11121686","journal-title":"Antibiot (Basel)"},{"issue":"10","key":"5109_CR40","doi-asserted-by":"publisher","first-page":"acmi000413","DOI":"10.1099\/acmi.0.000413","volume":"4","author":"C Nye","year":"2022","unstructured":"Nye C, Duckers J, Dhillon R (2022) Cefiderocol to manage chronic, multi-drug-resistant Burkholderia cepacia complex infection in a patient with cystic fibrosis: a case report. Access Microbiol 4(10):acmi000413. https:\/\/doi.org\/10.1099\/acmi.0.000413","journal-title":"Access Microbiol"},{"issue":"7","key":"5109_CR41","doi-asserted-by":"publisher","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","volume":"73","author":"NC Warner","year":"2021","unstructured":"Warner NC, Bartelt LA, Lachiewicz AM, et al (2021) Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections. Clin Infect Dis 73(7):e1754\u2013e1757. https:\/\/doi.org\/10.1093\/cid\/ciaa1847","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05109-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05109-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05109-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:57:16Z","timestamp":1748336236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05109-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["5109"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05109-5","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of Hospital La Princesa, Madrid, on 3 November 2020 (Royal Decree 957\/2020), which served as central reference ethics committee. The study was compliant with all legal and regulatory requirements, the International Conference on Harmonisation Good Clinical Practice E6 guidelines and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"In accordance with Spanish regulations, patient consent was waived due to the retrospective design of the study as patients completed their treatment prior to study initiation; therefore, the study represented no harm for the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Julian Torre-Cisneros has received educational grants and fee for advisory activities from Shionogi, Pfizer, MSD, Menarini; and unrestricted research grants from Pfizer and MSD. Alex Soriano has received honoraria for lectures and advisory boards from Shionogi, Pfizer, Menarini, Angelini, Advance Pharma and Gilead, and grants from Pfizer and Gilead. Ricard Ferrer has received honoraria for lectures from Gilead, Menarini, MSD, Shionogi, and ThermoFisher; consulting fees from Cytosorbent, Inoterm, and Pfizer; and holds stocks or stock options from Grifols. Carmen De La Fuente Martos received honoraria from Shionogi & Co., Ltd., Osaka, Japan, for participation in this study. Jessica Sarda, A. Javier Gonzalez Calvo, Stefano Verardi, Andreas Karas are employees of Shionogi.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}